Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.

Mª Del Carmen ÁlamoSebastian OchenduszkoGuillermo CrespoMónica CorralJuana OramasPilar SanchoJavier MedinaFernando GaricanoPedro LópezBegoña Campos BaleaAnalia Rodríguez GarzottoEva Muñoz-Couselo

Published in: OncoTargets and therapy (2021)

The combination treatment with vemurafenib/cobimetinib results in an important impact on long-term survival, leading to a steady CR in one-third of the patients.

Keyphrases

clinical practice
end stage renal disease
ejection fraction
patient reported outcomes
patient reported